|Bid||1.740 x 900|
|Ask||1.750 x 900|
|Day's Range||1.700 - 1.900|
|52 Week Range||1.470 - 11.050|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2018 - May 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.88|
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
Investors need to pay close attention to Immune Design (IMDZ) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.
Immune Design's stock price dropped more than 30 percent on the decision, which pushes the prospects of FDA approval several years into the future.
Shares of Immune Design Corp. took a 42% dive toward a record low in premarket trade Friday, after the immunotherapy company said it discontinued its CMB305 cancer vaccine program. The company said late Thursday it made the design after an early analysis of a phase 2 study showed CMB305 combined with Tecentriq is not likely to show a survival benefit in relapsed synovial sarcoma patients. The company said it plans to focus on accelerating and expanding the development of its lymphoma therapy, G100. Leerink analyst Jonathan Chang cut his rating on Immune Design to market perform from outperform and slashed his price target on the stock (IMDZ) to $3 from $7. Chang wrote in a note to clients that while he views the decision to focus on G100 as a positive, "in the context of past disappointments that have pressured IMDZ shares, we believe this recent update could add to investor concerns on company execution, which has been a critical part of the IMDZ story." The stock had lost 74% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 2.9% and the S&P 500 has gained 7.0%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...
G100 development to accelerate in follicular lymphoma and beyondCMB305 to be deprioritized to support focus on G100Cash runway extended into 2021Conference call at 2:00 pm.
The big shareholder groups in Immune Design Corp (NASDAQ:IMDZ) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...
NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Immune Design Corp (NASDAQ:IMDZ), a US$183.0m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...
Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018-- Immune Design, an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming ...
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD ...
Immune Design (IMDZ) delivered earnings and revenue surprises of 3.33% and 17.97%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Seattle-based company said it had a loss of 29 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
G100 advancing to late-stage development following FDA feedback Conference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018-- Immune Design, an immunotherapy company ...
Immune Design (IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report second quarter 2018 financial results after the close of U.S. financial markets on Wednesday, August 1, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2018 to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Immune Design Corp. (NASDAQ: IMDZ), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).